Figure 1From: Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in transgenic mouse models of frontotemporal lobar degeneration and Alzheimer’s diseaseEffect of 17-AAG on survival in JNPL3 and Tg2576 mice. For each dose of 17-AAG, number of mice surviving to the end of the three-month treatment period at age 11 months or dying during treatment. Left: JNPL3 mice (tau transgenic). Right: Tg2576 mice (APP transgenic).Back to article page